Phenothrin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Phenothrin: From Topical Ectoparasiticide Use to Aleutian Mink Disease
One-Sentence Summary
Phenothrin is a pyrethroid-class topical insecticide/ectoparasiticide (used for external pest and flea control); no formal indication text or licensed UK product exists in this evidence pack. The TxGNN model predicts a possible link to Aleutian mink disease, but this is a model-only signal — no clinical trials, no literature, and no supporting mechanism currently back it up.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally documented — described only as a topical pyrethroid ectoparasiticide (flea/insect control); no approved indication text on file |
| Predicted New Indication | Aleutian mink disease |
| TxGNN Prediction Score | 97.21% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Phenothrin is not available in this evidence pack (flagged as a High-severity data gap, DG002). What is known from the supporting rationale text is that Phenothrin is a pyrethroid that acts on insect sodium channels and is used exclusively as a topical, external ectoparasiticide — it has no documented systemic pharmacology in mammals.
Aleutian mink disease is caused by a parvovirus and produces its pathology through immune-complex deposition, not through any pathway plausibly modulated by an insect neurotoxin. The evidence pack’s own mechanistic assessment explicitly states there is no known biological rationale connecting Phenothrin to this disease.
Taken together with the fact that all ten of the top TxGNN predictions for this drug carry the same L5/Hold status and similarly worded disclaimers (several explicitly describing themselves as “prediction noise” arising from graph-structural proximity rather than pharmacology), this candidate should be read as a low-confidence, structural artefact of the knowledge graph rather than a genuine repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Phenothrin currently holds no UK marketing authorisation (0 licences on record), so no MHRA product entry or SmPC exists to reference for this candidate.
Safety Considerations
No structured safety data is available in this evidence pack — key warnings, contraindications and drug interaction data are all unpopulated (flagged as a Blocking data gap, DG001). Because there is no UK-authorised product, no SmPC exists to consult. Any future development would require ground-up toxicology and safety assessment (e.g. from pesticide regulatory dossiers) before this candidate could enter a formal safety review stage.
Conclusion and Next Steps
Decision: Hold
Rationale: This is a model-only (L5) prediction with zero clinical trial or literature support, an explicit lack of biological mechanism connecting the drug to the disease, and no UK marketing presence to build a safety case on. The evidence pack itself argues against pharmacological plausibility.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain regulatory labelling/warnings and contraindications before any safety review can start
- Resolve DG002 (High): confirm a verified mechanism of action via DrugBank or primary pharmacology literature
- Independent preclinical evidence for any antiviral or immunomodulatory activity relevant to parvovirus-driven disease
- Clarify translational relevance, given the predicted indication is a veterinary (mink) disease rather than a human condition
- Given all 10 ranked predictions for this drug share the same unsupported L5/Hold profile, treat this entire candidate batch as low priority pending stronger signal from an updated TxGNN run or new evidence sources
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.